Biomerieux Logo

For Assessing Risk Over Time

In the ICU, in the Emergency Department, in patient wards — VIDAS® B•R•A•H•M•S PCT™ (Procalcitonin) can aid in sepsis risk assessment and deliver key data related to bacterial infection severity, at initial presentation and over the course of treatment. In managing critically ill patients, serial measurements over multiple days can support assessment of that patient’s response to therapy. As the infection is controlled, PCT will decline daily.1


Sick child, doctors hurrying to correctly assess cause

The Procalcitonin Monitoring Sepsis Study

  • 858 adult patients with sepsis recruited across 13 investigational sites in the United States
  • The mortality rate was 2-fold higher when PCT did not drop by more than 80 percent from baseline to Day 4
  • The initial PCT level (<— 2.0 ng/mL or > 2.0 ng/mL) provided important additional information about the mortality risk when evaluating the patient’s clinical course with PCT measurements on subsequent days

The change of PCT over time aids in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock.


It's Different from Other Biomarkers

Biomarker comparison chart showing higher plasma concentration of PCT for testing purposes

  • PCT is distinguished from other markers by its early and highly specific increase in response to severe systemic bacterial infections and sepsis3,4
  • Increased PCT levels can be observed within just 3–6 hours after an infectious challenge5
  • With a 24-hour half-life, PCT decline is consistent with an improving clinical condition3,5


Unique Kinetics of PCT Are Strong Indicators of Mortality Risk Over Time2

Chart showing PCT kinetics over time

Assessing PCT kinetics over time provides valuable information regarding patient disposition, response to treatment and likelihood of survival


1. Soni NJ, Samson DJ, Galaydick JL et al: Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis. J Hosp Med 2013;8(9):530-540.

2. MOSES Clinical Trial Data. On file at bioMérieux Inc.

3. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164:396-402.

4. Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000;28:977-83.

5. Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med. 1998;24:888-892.


Watch the inspiring video of sepsis survivor Patricia Cragen and her family as they experience a once in a lifetime event at Strike Out Sepsis Day with the St. Louis Cardinals on August 31, 2015. Watch Video >

See highlights from the Second National Forum on Sepsis, held September 16, 2015 in Washington, DC, and learn more about the Rory Staunton Foundation’s initiatives to raise awareness and knowledge about sepsis. Watch Video >


  • VIDAS® B•R•A•H•M•S PCT™ for the Clinician - Download
  • Procalcitonin: A Novel Biomarker for Bacterial Infections and Sepsis - Download
  • Procalcitonin Over Time - Download
  • Blood Culture: A Key Investigation for Diagnosis of Bloodstream Infections - Download